CLINICAL TRIALS PROFILE FOR ESMOLOL HYDROCHLORIDE

All Clinical Trials for esmolol hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	National Health and Medical Research Council, Australia	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	The George Institute	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00302692 ↗	Use of Beta Blockers in Elderly Trauma Patients	Unknown status	American Heart Association	Phase 2	2005-12-01	Advances in medical care have increased the proportion of elderly Americans and enabled them to remain more physically active. This has resulted in an unprecedented increase in the number of geriatric patients admitted to trauma centers. The elderly constitute 23% of trauma center admissions, but 36% of all trauma deaths. This disproportionately high mortality is attributable to a higher prevalence of pre-existing conditions, particularly, cardiac disease. Multi-system injuries result in critical cardiac stress. Although beta-blockade has been shown to decrease morbidity and mortality in patients at risk for myocardial infarction after elective surgery, their use in trauma patients with potential underlying cardiac disease has not been previously studied. We hypothesize that routine administration of beta-blockers after resuscitation will reduce morbidity and mortality in elderly trauma patients with, or at risk for, underlying cardiac disease. This study is a randomized, prospective clinical trial. One cohort will receive routine trauma intensive care, and the other, the same care plus beta-blockade after completion of resuscitation. The primary outcome will be mortality. Secondary outcomes include MI, length of stay, organ dysfunction, cardiac, and other complications. Changes in outcome may not be due to reduction in myocardial oxygen demand and heart rate. Laboratory studies demonstrate that circulating inflammatory cytokines contribute to cardiac risk in trauma patients, and their production is influenced by adrenergic stimulation. We will measure circulating IL-6, TNF alpha, IL-1beta, and measure NF-kB and p38 MAP kinase activation in peripheral blood leukocytes, and determine the effect of beta-blockade on the production of these inflammatory markers. Finally, the wide variation in patient response to beta-blockers is attributed to genetic variability in the adrenergic receptor. Therefore, we will identify single nucleotide polymorphisms (SNPS) within the beta-adrenergic receptor, and determine their effects on mortality and response to beta-blockade. This study will provide the first randomized, prospective trial designed to reduce morbidity and mortality in elderly trauma patients at risk for cardiac disease. The laboratory and genetic component will provide additional insights that may explain treatment effects, lead to new therapeutic strategies, and have the potential to lead to additional areas of investigation.
NCT00302692 ↗	Use of Beta Blockers in Elderly Trauma Patients	Unknown status	University of Texas Southwestern Medical Center	Phase 2	2005-12-01	Advances in medical care have increased the proportion of elderly Americans and enabled them to remain more physically active. This has resulted in an unprecedented increase in the number of geriatric patients admitted to trauma centers. The elderly constitute 23% of trauma center admissions, but 36% of all trauma deaths. This disproportionately high mortality is attributable to a higher prevalence of pre-existing conditions, particularly, cardiac disease. Multi-system injuries result in critical cardiac stress. Although beta-blockade has been shown to decrease morbidity and mortality in patients at risk for myocardial infarction after elective surgery, their use in trauma patients with potential underlying cardiac disease has not been previously studied. We hypothesize that routine administration of beta-blockers after resuscitation will reduce morbidity and mortality in elderly trauma patients with, or at risk for, underlying cardiac disease. This study is a randomized, prospective clinical trial. One cohort will receive routine trauma intensive care, and the other, the same care plus beta-blockade after completion of resuscitation. The primary outcome will be mortality. Secondary outcomes include MI, length of stay, organ dysfunction, cardiac, and other complications. Changes in outcome may not be due to reduction in myocardial oxygen demand and heart rate. Laboratory studies demonstrate that circulating inflammatory cytokines contribute to cardiac risk in trauma patients, and their production is influenced by adrenergic stimulation. We will measure circulating IL-6, TNF alpha, IL-1beta, and measure NF-kB and p38 MAP kinase activation in peripheral blood leukocytes, and determine the effect of beta-blockade on the production of these inflammatory markers. Finally, the wide variation in patient response to beta-blockers is attributed to genetic variability in the adrenergic receptor. Therefore, we will identify single nucleotide polymorphisms (SNPS) within the beta-adrenergic receptor, and determine their effects on mortality and response to beta-blockade. This study will provide the first randomized, prospective trial designed to reduce morbidity and mortality in elderly trauma patients at risk for cardiac disease. The laboratory and genetic component will provide additional insights that may explain treatment effects, lead to new therapeutic strategies, and have the potential to lead to additional areas of investigation.
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	PDL BioPharma, Inc.	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	OSF Healthcare System	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.

Clinical Trial Conditions for esmolol hydrochloride

Condition Name

Condition Name for esmolol hydrochloride
Intervention	Trials
Septic Shock	10
Anesthesia	6
Hypertension	6
Postoperative Pain	6

Condition MeSH

Condition MeSH for esmolol hydrochloride
Intervention	Trials
Shock	12
Shock, Septic	12
Pain, Postoperative	9
Tachycardia	6

Clinical Trial Locations for esmolol hydrochloride

Trials by Country

Trials by Country for esmolol hydrochloride
Location	Trials
United States	28
China	26
Egypt	17
Brazil	10
France	7

Trials by US State

Trials by US State for esmolol hydrochloride
Location	Trials
California	6
Illinois	5
Utah	2
North Carolina	2
New York	2

Clinical Trial Progress for esmolol hydrochloride

Clinical Trial Phase

Clinical Trial Phase for esmolol hydrochloride
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	2
PHASE2	2

Clinical Trial Status

Clinical Trial Status for esmolol hydrochloride
Clinical Trial Phase	Trials
Completed	47
Unknown status	25
Recruiting	25

Clinical Trial Sponsors for esmolol hydrochloride

Sponsor Name

Sponsor Name for esmolol hydrochloride
Sponsor	Trials
Ain Shams University	5
The University of Hong Kong	4
Baxter Healthcare Corporation	4

Sponsor Type

Sponsor Type for esmolol hydrochloride
Sponsor	Trials
Other	153
Industry	15
OTHER_GOV	1

Last updated: July 28, 2026

Esmolol Hydrochloride clinical trials update, market analysis, and revenue projection (2026-2036)

Esmolol hydrochloride is an intravenous, ultra–short-acting beta-1 blocker used in controlled, acute settings such as perioperative tachyarrhythmias and stress-related heart rate control. Commercially, the market is constrained by route-of-administration specificity (IV), narrow use windows, and the availability of cheaper beta blockers, while uptake is supported by anesthesiology and critical-care protocols.

This update compiles the core market mechanics that drive demand and sets out a projection framework for 2026-2036 centered on (1) acute-care procedure volumes, (2) adoption in perioperative and ICU pathways, (3) supply availability and generic competitive intensity, and (4) regulatory and label constraints.

What is the current clinical trials pipeline for esmolol hydrochloride (IV beta blocker)?

Which trial objectives dominate esmolol hydrochloride research

Clinical investigation of esmolol hydrochloride typically targets:

• Rapid heart-rate control in acute settings (perioperative and ICU tachycardia)
• Comparisons versus other beta blockers or rate-control strategies
• Dosing optimization for short duration, such as titration studies
• Outcome endpoints that map to hemodynamic stability and time-to-target heart rate

How to interpret “pipeline activity” for this asset class

Esmolol hydrochloride is an established IV medicine. For this drug category, new trials often function as:

• Bioequivalence and formulation studies for generics or authorized products
• Comparative effectiveness studies in narrow acute indications rather than large registrational programs
• Pharmacokinetic/pharmacodynamic (PK/PD) bridging to refine dosing algorithms

What the “practical pipeline” tends to look like

In mature IV beta blockers, the incremental clinical development burden shifts toward:

• Manufacturing and formulation improvements (stability, infusion compatibility)
• Competitive lifecycle events that change supply rather than therapeutic positioning
• Trials in specific perioperative workflows (cardiac and noncardiac surgery), rather than broad new indications

Data coverage constraint

No reliable, current (2026) trial registry extract is included here because the prompt does not provide a source set or a timeframe, and complete accuracy cannot be guaranteed without a live database pull.

How big is the esmolol hydrochloride market today, and what drives demand?

Demand drivers

Esmolol demand is pulled by acute-care utilization patterns:

• Perioperative monitoring and tachycardia management in anesthesia and surgical pathways
• ICU and emergency management of sinus tachycardia and selected supraventricular tachycardias, where rapid titration and reversibility matter
• Cardiac surgery and peri-procedural heart-rate control protocols

Supply and pricing dynamics

Key market constraints:

• IV manufacturing cost and distribution requirements
• Generic entry pressure on pricing once patents and exclusivities are exhausted (product-line competition)
• Competition from inexpensive beta blockers (e.g., metoprolol) and from non-beta rate-control strategies in some workflows
• Tender dynamics for hospital supply contracts

Competitive landscape (what matters commercially)

The practical competitive set includes:

• Authorized generics and true generics of IV esmolol hydrochloride
• Hospital formularies that standardize IV beta blocker usage
• Alternatives that may be selected based on drug-device compatibility (infusion pumps, compatibility with co-administered IV fluids)

When does esmolol hydrochloride lose exclusivity, and how does that affect market share?

Exclusivity and patent effects in mature IV markets

For established IV generics, market share shifts are driven by:

• The timing of patent expirations and any related litigation or settlement
• Regulatory exclusivities (where applicable to specific products, presentations, or manufacturing changes)
• Label and formulation differences that can preserve differentiation (concentration, vial size, excipients, infusion compatibility)

Why “loss of exclusivity” is usually the main step-change

After exclusivity events, the biggest revenue inflections typically come from:

• Multiple ANDA filings and competitive hospital contracting
• Rapid erosion of average selling price (ASP)
• Reduced prescriber preference for branded supply

Data coverage constraint

A definitive exclusivity timeline cannot be produced here without the specific reference product(s), label strengths, and the Orange Book listing history tied to those exact SKUs.

What is the current FDA status of esmolol hydrochloride (Orange Book, approvals, and ANDAs)?

Regulatory pathway overview for this drug

Esmolol hydrochloride’s IV presentation is typically supplied via:

• Original NDA approval for the reference product, if present for a given strength and package
• ANDAs for generics covering specific dosage strengths and packaging
• Potential supplemental applications for manufacturing changes or formulation adjustments

Where competitive entry is determined

For market access and projection modeling, the gating item is SKU-level FDA status:

• Which strengths are listed
• Which manufacturers are current
• Whether there are listed patents that can block generic approval
• Whether any exclusivity applies to specific manufacturing methods or formulations

Data coverage constraint

A precise Orange Book status map is not provided because the prompt includes no FDA/Orange Book reference identifiers and does not supply a current extract.

What generic entry risks exist for esmolol hydrochloride (ANDA, Paragraph IV, litigation)?

Typical litigation and settlement pattern in IV beta blockers

For hospital-administered IV drugs, Paragraph IV risk manifests through:

• Challenge filings on listed patents
• Settlement agreements that set “skinny launch” timing or non-launch covenants
• Product-line segmentation that limits early entry to specific strengths or pack sizes

Operational risks that matter to revenue projection

• Date-dependent launch disruptions (or delayed supply)
• Contracting lead times in hospital procurement
• Switching costs in pharmacy formularies and protocol lock-in

Data coverage constraint

No Paragraph IV dossier is included because litigation records require a patent-by-patent and NDA/ANDA-by-ANDA mapping to be accurate.

Which formulations and routes are protected for esmolol hydrochloride (dosing strengths, infusion compatibility)?

How formulation protection usually shows up

In IV cardiovascular drugs, differentiation can involve:

• Concentration and vial size
• Stability and compatibility with common infusion diluents
• Manufacturing controls that affect shelf-life and infusion performance
• Excipients affecting pH and solubility stability

What this means for market forecasting

If multiple SKUs exist, each SKU can have a separate competitive timeline:

• Strongest near-term risk is typically on the most widely demanded strength and packaging
• Niche strengths and specialty pack sizes often face slower uptake

Data coverage constraint

A formulation-by-formulation protection map needs the specific marketed presentations and their listed patents, which is not present in the prompt.

How does esmolol hydrochloride compare with competing IV beta blockers for acute heart rate control?

Key differentiators used in hospital protocols

Esmolol’s commercial positioning in acute care is typically tied to:

• Ultra–short duration that supports rapid titration and fast offset
• Predictable hemodynamic control under monitored settings
• Use alignment with anesthesia and perioperative care workflows

Where competitors displace demand

Esmolol faces substitution risk when:

• Protocols shift to longer-acting beta blockers with acceptable titration profiles
• Alternative rate-control agents are preferred based on institutional practice
• Cost pressure drives pharmacy tender choices toward lower-cost options

Projection implication

A credible forecast generally assumes:

• Short-term revenue resilience from protocol fit
• Medium-term pricing pressure from generic competition
• Segment-specific stability where esmolol provides operational advantages

Market projection for esmolol hydrochloride (2026-2036): base, downside, upside

Projection approach

Because SKU-level pricing and SKU-level unit volumes vary by region and by hospital contracting cycles, projections should be modeled as:

1. Procedure and ICU demand pool growth (top-down utilization)
2. Share of acute-care pathways using IV esmolol (adoption/retention)
3. ASP erosion due to generic competition and supply intensity
4. Occasional step changes from supply disruptions or tender reallocations

Base case assumptions (directional, not SKU-specific)

• Demand grows at or slightly above general healthcare volume growth due to continued perioperative and ICU use.
• ASP trends down due to increased generic supply and tender competition.
• Net revenue stabilizes through volume resilience but does not recover to historical peak pricing.

Downside case assumptions

• Faster ASP erosion from aggressive hospital contracting.
• Greater substitution to alternative rate-control strategies.
• Supply normalization reduces differentiation and accelerates switching.

Upside case assumptions

• Protocol consolidation keeps esmolol within preferred perioperative and critical-care algorithms.
• Slower competitive pricing erosion in key regions due to supply constraints or limited manufacturer participation.
• Expanded use in targeted settings where rapid titration is valued.

Quantitative revenue forecast

No numeric market size, unit volume, or ASP inputs are provided in the prompt, and producing precise dollar figures without cited sources would violate the accuracy requirement. Therefore, a quantified projection table is not included.

What product lifecycle events could change the trajectory (2026-2036)?

Manufacturing and supply issues

Short IV cardiovascular products are exposed to:

• Batch-level supply disruptions
• Contract manufacturing constraints
• Regulatory quality actions that temporarily limit availability

Regulatory label and utilization shifts

If labeling or real-world protocols tighten around specific scenarios, adoption can shift without large clinical evidence changes.

Generic entry waves

The largest forecast risk is the timing and speed of:

• Multiple approvals across strengths
• Concurrent market releases post-exclusivity or post-litigation

Key Takeaways

• Esmolol hydrochloride is a mature IV beta-1 blocker with demand anchored in perioperative and acute-care heart rate control workflows.
• The commercial trajectory is primarily shaped by hospital procurement dynamics and generic competitive intensity rather than a broad late-stage clinical growth thesis.
• A precise clinical trials update and a quantified revenue projection require current, source-backed registry and regulatory extract; those inputs are not included in the prompt, so this update focuses on the decision-relevant market mechanisms and lifecycle factors that determine outcomes.

FAQs

1. What indications drive the majority of esmolol hydrochloride use in hospitals?
2. How does IV beta blocker titration influence formulary selection versus longer-acting agents?
3. What events typically trigger ASP declines for established injectable cardiovas­cular generics?
4. How do SKU-specific strengths and packaging affect generic substitution and revenue erosion?
5. What are the main compliance and supply risks for IV cardiovascular products competing on tenders?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. (Accessed via FDA Orange Book database).